Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 20/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.56 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4424859 | 0.82 | P2RY1 (0.69) | P2RY1 | |
| SCHEMBL4429645 | 0.81 | P2RY1 (1.00) | P2RY1 | |
| SCHEMBL4432169 | 0.81 | P2RY1 (0.68) | P2RY1 | |
| SCHEMBL4429719 | 0.78 | P2RY1 (1.00) | P2RY1 | |
| SCHEMBL1382421 | 0.78 | P2RY1 (1.00) | P2RY1OPRM1OPRD1OPRK1P2RX1 | |
| SCHEMBL4429759 | 0.78 | P2RY1 (1.00) | P2RY1 | |
| SCHEMBL4429660 | 0.78 | P2RY1 (1.00) | P2RY1 | |
| SCHEMBL4422600 | 0.76 | P2RY1 (1.00) | P2RY1OPRM1OPRD1OPRK1P2RX1 | |
| SCHEMBL17088082 | 0.74 | P2RY1 (0.71) | P2RY1 | |
| SCHEMBL4422614 | 0.73 | P2RY1 (1.00) | P2RY1OPRM1OPRD1OPRK1P2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1984655-B | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB CO. (US) | 2011-11-30 | — | — | CN | claimed |
| EP-1750704-B1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2009-07-22 | — | — | EP | claimed |
| CN-1984655-A | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2007-06-20 | — | — | CN | claimed |
| US-20050261244-A1 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-24 | — | — | US | claimed |
| CN-1984655-B | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB CO. (US) | 2011-11-30 | — | — | CN | disclosed |
| EP-1750704-B1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2009-07-22 | — | — | EP | disclosed |
| US-7550499-B2 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
| CN-1984655-A | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2007-06-20 | — | — | CN | disclosed |
| US-20050261244-A1 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261244-A1 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | P2RY1, P2RY11, P2RY2 | P2RY1 1/4885OPRM1 128/4885OPRD1 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.